Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 17,221

Document Document Title
WO/2018/073602A1
The present invention concerns the identification of inhibitors of ubiquitin specific protease 7 (USP7), and methods of use thereof.  
WO/2018/070824A1
Disclosed are a compound represented by chemical formula 1; an organic electric element including a first electrode, a second electrode, and an organic material layer between the first electrode and the second electrode; and an electroni...  
WO/2018/070836A1
An organic electronic device and an electronic apparatus comprising same are disclosed. The organic electronic device comprises: a compound represented by chemical formula (1); a first electrode; a second electrode; and an organic layer ...  
WO/2018/071606A1
The present disclosure relates to bifunctional compounds, which find utility to degrade and (inhibit) Androgen Receptor. In particular, the present disclosure is directed to compounds, which contain on one end a cereblon ligand which bin...  
WO/2018/071314A1
There are described RORĪ³ modulators of the formula (I), and formula (II) or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein all substituents are defined herein. Also provided are pharm...  
WO/2018/064510A1
Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have the following structure (I), or a pharmaceutically acceptable salt, tautomer, stereoisomer or prodrug thereof, wherein B, W, X, Y, R1, R...  
WO/2018/062778A1
The present disclosure relates to an organic electroluminescent device comprising a first electrode, a second electrode facing the first electrode, a light-emitting layer between the first electrode and the second electrode, and an elect...  
WO/2018/064557A1
The present disclosure relates to substituted fused bi- or tri- heterocyclic compounds. The present disclosure also relates to pharmaceutical compositions containing these compounds and methods of treating a disorder (e.g., sickle cell a...  
WO/2018/063955A1
The present invention provides certain substituted chromane, isochromane, and dihydroisobenzofuran compounds of formula (I) or a pharmaceutically acceptable salt thereof, wherein ring A is a moiety selected from (II), (III), (IV), and (V...  
WO/2018/060218A1
The present invention relates to diazadibenzofurane or diazadibenzothiophene derivatives which are substituted with carbazole structures, in particular for use in electronic devices. The invention further relates to a method for producin...  
WO/2018/060482A1
The present application relates to new fluorescent dyes and their uses as fluorescent labels. The compounds may be used as fluorescent labels for nucleotides in nucleic acid sequencing applications.  
WO/2018/060307A1
The present invention relates to diazadibenzofurane or diazadibenzothiophene derivatives which are substituted with carbazole, fluorene, phenanthrene, benzofuran and/or benzothiophene groups, in particular for use in electronic devices. ...  
WO/2018/055402A1
The present invention relates to compounds of formula (I), and salts and solvates thereof, that function as inhibitors of cell division cycle 7 (Cdc7) kinase enzyme activity: (Formula (I)) wherein X, R1, R2, and n are each as defined her...  
WO/2018/056619A1
The present invention relates to a novel compound having excellent thermal stability and luminescent ability, and to an organic electroluminescent element having enhanced characteristics such as luminous efficiency, driving voltage, and ...  
WO/2018/056524A1
The present invention provides: a compound with an amine group, represented by [chemical formula A] or [chemical formula B]; and an organic light emitting element comprising the same. In [chemical formula A] or [chemical formula B], ring...  
WO/2018/054270A1
Provided in the present invention are a novel velpatasvir crystal and a preparation method therefor. The structure of formula (I) compound of the present invention is a represented below. Crystal A of formula (I) compound produced per th...  
WO/2018/054304A1
A furoquinolinedione compound represented by formula (I), a prodrug, a stereoisomer, or a pharmaceutically-acceptable salt thereof, a pharmaceutical composition thereof, a preparation method therefor and a medicinal use thereof.  
WO/2018/050584A1
The invention relates to spirobifluorene derivatives which are substituted with electrone transport groups, in particular for use in electronic devices. The invention further relates to a method for producing the compounds according to t...  
WO/2018/050583A1
The present invention relates to carbazole derivatives which are substituted with electron transport groups, in particular for use in electronic devices. The invention further relates to a method for producing the compounds according to ...  
WO/2018/052244A1
The present disclosure relates to an organic electroluminescent device. The organic electroluminescent device of the present disclosure comprises a specific combination of an electron buffer material and an electron transport material wh...  
WO/2018/050107A1
An organic light-emitting material and application thereof in an OLED are disclosed. The material has good fluorescence quantum efficiency and electroluminescence efficiency and good heat stability, and therefore the material can serve a...  
WO/2018/052967A1
The present invention includes novel substituted bicyclic (such as 4-substituted-chromane-8-carboxamide compounds), and compositions comprising the same, that can be used to treat or prevent hepatitis B virus (HBV) infections in a patien...  
WO/2018/050510A1
The invention relates to novel 7-substituted 1-aryl-naphthyridine-3-carboxylic acid amides, to methods for producing the same, to the use thereof either alone or in combination in the treatment and/or prevention of diseases and to their ...  
WO/2018/045971A1
The present invention provides a pyrido five-element aromatic ring compound, and a preparation method therefor and a use thereof. The compound provided in the present invention has an inhibitory effect on wild-type and/or mutant EZH2, an...  
WO/2018/043567A1
The purpose of the present invention is to discover a cytotoxic anticancer drug that serves as a common substrate for both ABCB1 and ABCG2 which are suppressed in human pluripotent stem cells, and to provide a method for efficiently remo...  
WO/2018/042362A1
The present invention relates to compounds of formula (I), or their isotopic forms, stereoisomers, tautomers or pharmaceutically acceptable salt (s) thereof as muscarinic M1 receptor positive allosteric modulators (M1 PAMs). The present ...  
WO/2018/042437A1
Color conversion films for a LCD (liquid crystal display) having RGB (red, green, blue) color filters, as well as such displays, formulations, precursors and methods are provided, which improve display performances with respect to color ...  
WO/2018/043761A1
Specifically substituted aza-dibenzofurans and aza-dibenzothiophenes of formula (I) and their use in electronic devices, especially electroluminescent devices. When used as charge transport material, charge blocker material and/or host m...  
WO/2018/042377A1
The present invention relates to substituted indazole compounds, their pharmaceutically acceptable salts, and their isomers, steroisomers, atropisomers, conformers, tautomers, polymorphs, hydrates or solvates. The present invention also ...  
WO/2018/038544A1
The present invention provides an organic electric device which can achieve a high luminous efficiency and a low driving voltage thereof and significantly improve the lifetime of the device, by using a mixture of a compound according to ...  
WO/2018/039190A1
A kit for treating psychosis by administering a pharmaceutically acceptable liquid composition of Asenapine to oral mucosa includes a formulation having Asenapine, or a pharmaceutically acceptable salt or hydrate thereof, ethanol, and wa...  
WO/2018/033088A1
Provided are a five-membered ring substituted compound having xanthone as the core and applications thereof. The compound has xanthone as the parent core and is connected to an aromatic heterocyclic group, thereby breaking molecular symm...  
WO/2018/033820A1
A novel organic compound is provided. That is, a novel organic compound that is effective in improving the element characteristics and reliability is provided. The organic compound has a benzofuroquinoxaline skeleton or a benzothienoquin...  
WO/2018/033631A1
The present invention relates to polymorphic forms of marizomib (e.g., Morphic Form I). The morphic forms can be used alone and in pharmaceutical compositions for the treatment of disease.  
WO/2018/033086A1
Disclosed are a compound having xanthone as the core and applications thereof in an organic electroluminescent component. The compound has xanthone as the parent core and is connected to an aromatic heterocyclic group, thereby breaking m...  
WO/2018/034444A1
Disclosed are: a compound represented by chemical formula 1; an organic electronic element comprising a first electrode, a second electrode, and an organic layer between the first electrode and the second electrode; and an electronic dev...  
WO/2018/034517A1
Provided are: an organic electronic element using, as a phosphorescent host material, a mixture of a compound according to the present invention, thereby enabling the organic electronic element to achieve high luminous efficiency and low...  
WO/2018/033631A9
The present invention relates to polymorphic forms of marizomib (e.g., Morphic Form I). The morphic forms can be used alone and in pharmaceutical compositions for the treatment of disease.  
WO/2018/034443A1
Disclosed are a compound represented by chemical formula 1, an organic electric element including a first electrode, a second electrode, and an organic layer disposed between the first and the second electrode, and an electronic device c...  
WO/2018/028665A1
Provided is a method for preparing an intermediate of 6-arylaminopyridonecarboxamide compound as an MEK inhibitor, comprising preparing a compound of formula (III) as an intermediate of 6-arylaminopyridonecarboxamide compound using a com...  
WO/2018/029288A1
The invention is concerned with the compounds of formula I: (I) and pharmaceutically acceptable salts thereof where R1 is a substituted or unsubstituted phenyl or a fused bicyclic comprising a substituted or unsubstituted phenyl. In addi...  
WO/2018/030382A1
According to the present invention, a compound represented by general formula (I), a tautomer, stereoisomer or pharmaceutically acceptable salt of the compound, or a solvate of the compound, the tautomer, the stereoisomer or the pharmace...  
WO/2018/026371A1
Compounds of formula I: I are disclosed, as are pharmaceutical compositions containing such compounds. Methods of treating neurological or psychiatric disorders in a patient in need are also disclosed. Such disorders include depression, ...  
WO/2018/025722A1
[Problem] To provide a novel method for producing an intermediate of biotin, which is capable of improving the yield of an amide alcohol compound that is the intermediate of biotin. [Solution] A method for producing an amide alcohol comp...  
WO/2018/026197A1
A mixture of compounds according to the present invention is used as a phosphorescent host material, thereby achieving the high light emitting efficiency and low driving voltage of an organic electric element; and providing an organic el...  
WO/2018/025590A1
The present invention addresses the problem of providing a method for producing, with a high yield, a nitrogen-containing heterocyclic compound having a high purity, superior production suitability, and superior environmental suitability...  
WO/2018/024224A1
A nitrogen-containing tricyclic compound which acts as modulator of FXR, or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, and the ...  
WO/2018/026877A1
The invention relates to a process for preparing substituted quinolin-4-ol compounds useful for preparing protein tyrosine kinase (PTK) inhibitors which are useful in treating cancer.  
WO/2018/023072A3
Disclosed are compounds of formula (I), and pharmaceutical compositions containing such compounds. Methods of treating neurological or psychiatric disease and disorders in a subject in need are also disclosed.  
WO/2018/021737A1
Provided are an organic electronic element and an electronic device thereof, the element using a mixture of a compound, of the present invention, as a phosphorescent host material such that high light-emitting efficiency and a low drivin...  

Matches 1 - 50 out of 17,221